Cha Byung Hyo, Song Ha Hun, Kim Young Nam, Jeon Won Jung, Lee Sang Jin, Kim Jin Dong, Lee Hak Hyun, Lee Ban Seok, Lee Sang Hyub
Digestive Disease Center, Department of Internal Medicine, Cheju Halla General Hospital, Doreongno 65, Jeju 690-766, Korea.
Korean J Gastroenterol. 2014 Jan 25;63(1):32-8. doi: 10.4166/kjg.2014.63.1.32.
BACKGROUND/AIMS: Percutaneous cholecystostomy (PC) is an effective treatment for cholecystitis in high-risk surgical patients. However, there is no definitive agreement on the need for additional cholecystectomy in these patients.
All patients who were admitted to Cheju Halla General Hospital (Jeju, Korea) for acute cholecystitis and who underwent ultrasonography-guided PC between 2007 and 2012 were consecutively enrolled in this study. Among 82 total patients enrolled, 35 underwent laparoscopic cholecystectomy after recovery and 47 received the best supportive care (BSC) without additional surgery.
The technical and clinical success rates for PC were 100% and 97.5%, respectively. The overall mean survival was 12.8 months. In the BSC group, mean survival was 5.4 months, and in the cholecystectomy group, mean survival was 22.4 months (p<0.01). However, there was no significant difference between these groups in multivariate analysis (relative risk [RR]=1.92; 95% CI, 0.77-4.77; p=0.16). However, advanced age (RR=1.05; 95% CI, 1.02-1.08; p=0.001) and higher class in the American Society of Anesthesiologists' physical status (RR=3.06; 95% CI, 1.37-6.83, p=0.006) were significantly associated with survival in the multivariate analysis. Among the 47 patients in the BSC group, the cholecystostomy tube was removed in 31 patients per protocol. Recurrent cholecystitis was not observed in either group of patients during the follow-up period.
In high-risk surgical patients, PC without additional cholecystectomy might be the best definitive management. Furthermore, the cholecystostomy drainage catheter can be safely removed in certain patients.
背景/目的:经皮胆囊造瘘术(PC)是高危手术患者胆囊炎的一种有效治疗方法。然而,对于这些患者是否需要额外进行胆囊切除术尚无定论。
连续纳入2007年至2012年期间因急性胆囊炎入住济州汉拿综合医院(韩国济州)并接受超声引导下PC的所有患者。在总共纳入的82例患者中,35例在康复后接受了腹腔镜胆囊切除术,47例接受了最佳支持治疗(BSC)且未进行额外手术。
PC的技术成功率和临床成功率分别为100%和97.5%。总体平均生存期为12.8个月。在BSC组中,平均生存期为5.4个月,在胆囊切除组中,平均生存期为22.4个月(p<0.01)。然而,在多变量分析中,这些组之间无显著差异(相对风险[RR]=1.92;95%可信区间,0.77 - 4.77;p=0.16)。然而,在多变量分析中,高龄(RR=1.05;95%可信区间,1.02 - 1.08;p=0.001)和美国麻醉医师协会身体状况分级较高(RR=3.06;95%可信区间,1.37 - 6.83,p=0.006)与生存期显著相关。在BSC组的47例患者中,按照方案有31例患者拔除了胆囊造瘘管。在随访期间,两组患者均未观察到复发性胆囊炎。
在高危手术患者中,不进行额外胆囊切除术的PC可能是最佳的确定性治疗方法。此外,在某些患者中可以安全地拔除胆囊造瘘引流导管。